Silexion Therapeutics Corp. (SLXN)
Market Closed
16 Jun, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
2. 71
-0.04
-1.4545%
$
1.31M Market Cap
- P/E Ratio
- Div Yield
305,872 Volume
- Eps
$ 2.75
Previous Close Want to track SLXN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer
Silexion Therapeutics Corp. SLXN released data on Wednesday from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces primary tumor growth and metastatic spread.
Benzinga | 1 year ago
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies
Silexion Therapeutics Corp. SLXN revealed new preclinical results demonstrating the synergistic efficacy of its SIL-204, in combination with components of first-line chemotherapy for pancreatic cancer.
Benzinga | 1 year ago
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise
Silexion Therapeutics Corp. SLXN stock is up more than 21.72% in pre-market trading Tuesday after the company revealed new findings from a Phase 2 trial for its first-generation product, LODER.
Benzinga | 1 year ago
